Testing ivonescimab after immunotherapy for nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new drug, ivonescimab, for people with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has come back or spread and no longer responds to standard treatments like chemotherapy and immunotherapy. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 21 years old.
- You have nasopharyngeal cancer that is EBV-positive (confirmed by a special test).
- Your cancer has returned or spread and cannot be cured with surgery or radiation.
- You have already tried at least one systemic treatment, including a platinum-based chemotherapy and an anti-PD-1 therapy (like Keytruda or Opdivo), and your cancer progressed (or you progressed within 6 months of such treatment given as part of a multimodal plan).
- You can provide a blood sample and a tumor sample (either a new biopsy or an archived one) for research.
- You are generally in good health (able to care for yourself, up and about, ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ivonescimab combined with the standard treatment (chemotherapy and radiation) for people with a high-risk type of nasopharyngeal cancer. It aims to see if this combination helps control the cancer better than standard treatment alone.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
This Phase 2 study compares standard chemotherapy (gemcitabine plus cisplatin) against the same chemotherapy plus pembrolizumab and bevacizumab. It aims to see which combination works better for EBV-positive nasopharyngeal cancer before any prior treatment.
This trial tests a combination of a drug that reactivates the Epstein-Barr virus (EBV) in the body plus an immunotherapy drug (PD-1 antibody) for people with nasopharyngeal cancer that has returned or spread. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This trial tests whether giving an immunotherapy drug called adebrelimab, based on levels of EBV DNA in the blood, can help people with advanced nasopharyngeal cancer. It is for those who have finished initial chemotherapy and still have signs of the virus or stable disease.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.